Where to Buy Tesamorelin Peptide in 2026

Where to buy tesamorelin has two different answers, and they are not interchangeable. Tesamorelin is an approved prescription medicine in the United States, dispensed under the Egrifta brand to a narrow patient group. It is also sold by the vial as laboratory research material, $115 per 10 mg as of September 2026 from the HEEZ catalog. The two are supplied under different rules, made to different specifications and meant for different purposes. This page covers the research channel and explains exactly where it stops.

Is tesamorelin for sale in the US?

Yes, through two separate channels.

The first is the pharmacy channel. Tesamorelin is the only FDA-approved therapy for abdominal fat accumulation in people with HIV (PMID 38905488). Per the U.S. prescribing information, it was first approved in 2010 and is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. It has been marketed in three successive formulations:

• the original Egrifta
• Egrifta SV from 2019
• Egrifta WR from 2025

That product moves through prescribers and pharmacies, and nothing on a research catalog is a version of it.

The second is the research-supply channel, where lyophilized tesamorelin is sold by the vial to laboratories. Researchers who need material can buy tesamorelin as a single 10 mg size at $115, prices as of September 2026 from the HEEZ catalog. Supply is restricted to qualified organizations and the material is for laboratory research use only, not for human consumption. The per-mg arithmetic and what that price buys over each published study window are worked through in the tesamorelin cost breakdown, so they are not repeated here.

Most compounds on a research catalog have only the second channel. Retatrutide, for example, holds no approval anywhere. Tesamorelin is the unusual case where an approved product and a research-grade material share one name, which is why the question of where to buy it needs a more careful answer than most. How a compound can sit on an approved-drug list and a research catalog at once is covered in why approved peptide lists differ.

How is prescription tesamorelin different from research-grade tesamorelin?

The molecule is the same. Almost everything around it is different.

The prescribing information describes tesamorelin as a synthetic analog of human growth hormone-releasing factor: the full 44 amino acid sequence, with a hexenoyl group, a six-carbon chain carrying a double bond at position 3, attached to the tyrosine at the N-terminus. It is prepared as an acetate salt. A research vial that is what it claims to be contains that same peptide.

What differs is the finished product. The approved drug is a formulated, sterile, preservative-free lyophilized powder. The current formulation lists 11.6 mg of tesamorelin per vial, equivalent to approximately 11.9 mg of tesamorelin acetate, together with hydroxypropyl betadex and mannitol as inactive ingredients. It is manufactured under drug-manufacturing controls, released against a registered specification and labeled for one indication. The label also states that the formulations are not substitutable with one another, because strength, reconstitution and storage differ between them. If two versions of the approved drug cannot be swapped freely, a research vial certainly cannot stand in for either.

Research-grade material carries none of that. There is no registered formulation, no labeled indication and no regulator reviewing each lot. What takes the place of all of it is documentation you can check yourself: the certificate of analysis. That makes the certificate the most important thing on any tesamorelin listing, and it is worth knowing what a good one looks like for this particular peptide.

What should a tesamorelin certificate of analysis show?

Two separate measurements, tied to the batch number on your vial.

Identity by mass spectrometry. The prescribing information gives the molecular formula of tesamorelin as C221H366N72O67S and its molecular weight as 5135.9 Da, expressed as the free base. An identity result should report an observed mass that matches that figure. This is the check that tells you the vial contains tesamorelin rather than a related sequence. It matters more here than for short peptides, because a 44-residue chain offers many more positions at which a synthesis can drop or truncate a residue, and those byproducts are close to the target in structure.

Purity by HPLC. High-performance liquid chromatography reports area percent, the share of detected material that is one dominant species. It says nothing about which species that is. A listing that shows purity without identity, or identity without purity, has reported half of what you need.

Two details are specific to this molecule. The single sulfur atom in that formula belongs to a methionine residue, and methionine is a common site of oxidation in peptides. An oxidized form weighs about 16 Da more than the parent, so it is visible to mass spectrometry, and its presence in a lot is a storage and handling signal worth looking for. Second, the approved product’s own label reports vial content two ways, as tesamorelin and as tesamorelin acetate, and the two masses differ. That is the distinction net peptide content captures on a research certificate: labeled milligrams are solid mass, and peptide is only part of the solid. When net peptide content is missing, treat the labeled figure as an upper bound.

A certificate that names only the compound tells you a product line was tested at some point. A certificate carrying the batch number printed on your vial tells you that lot was tested. On the HEEZ listing, every lot carries a batch-specific third-party certificate covering HPLC purity and MS identity, with purity stated as 99% or higher as measured. The order in which to read those fields, and what each one cannot tell you, is set out in a seven-point COA read.

What did the trials behind the approval actually show?

The pivotal evidence is a body-composition result in a defined population, and it is narrower than most descriptions of tesamorelin suggest.

In the 26-week randomized trial published in the New England Journal of Medicine, 412 patients with HIV and abdominal fat accumulation, 86% of them men, received a daily subcutaneous injection of 2 mg of tesamorelin or placebo (PMID 18057338). The primary endpoint was percent change in visceral adipose tissue on computed tomography. Visceral fat decreased by 15.2% on tesamorelin and increased by 5.0% on placebo. Triglycerides fell by 50 mg per deciliter against a rise of 9 mg per deciliter, and IGF-I rose by 81.0% against a fall of 5.0%, with P<0.001 for each comparison. Adverse events did not differ significantly between groups overall, though more patients in the tesamorelin group withdrew because of one. Glycemic measures did not differ significantly.

Two qualifications belong next to those numbers. The effect depends on continued exposure: visceral fat reductions held to week 52 in the extension phases of the two 26-week trials, while discontinuation was followed by reaccumulation (PMID 22050344). And the population was specific. These were adults with HIV-associated abdominal fat accumulation, not a general population, and the approval follows the trial.

Whether the effect extends further is an open research question rather than a settled one. TRIUMPH, a 48-week trial registered as NCT06554717, is testing 24 weeks of tesamorelin or placebo alongside a home-based exercise programme in 100 adults with HIV, followed by a 24-week extension (PMID 42419889). It has published a protocol and no results.

How does ordering research tesamorelin work?

As a catalog purchase with fixed terms, which are worth reading before the price.

HEEZ Research ships same day by UPS from Florida on orders placed before the 3 PM ET cutoff. Lyophilized material ships at ambient temperature, so there is no cold-chain surcharge on top of the vial price. One size is listed, 10 mg, so there is no tier to choose between. All sales are final. Supply is restricted to qualified organizations, for laboratory research use only.

Common questions about buying tesamorelin

Do you need a prescription to buy research tesamorelin? Research material is not dispensed against a prescription, because it is not a medicine. That is a statement about what the product is, not a route around the pharmacy channel. Research-grade tesamorelin is not the approved drug, is not manufactured or released as one, and is not for human use.

Is research tesamorelin the same as Egrifta? The peptide sequence is the same. The product is not. Egrifta is a formulated, sterile, labeled drug released against a registered specification. A research vial is a laboratory reagent documented by its certificate of analysis.

What sizes is tesamorelin sold in? One size on the HEEZ catalog: 10 mg, at $115, prices as of September 2026 from the HEEZ catalog.

Can a tesamorelin order be returned? No. All sales are final.

How fast does tesamorelin ship? Same day by UPS from Florida when the order is placed before 3 PM ET.